title: Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis.
abstract: Although adjunctive treatment with retinoids in concert with either psoralen-ultraviolet A (PUVA) or ultraviolet B (UVB) phototherapy has been a treatment option for chronic, moderate to severe plaque psoriasis for nearly two decades, acitretin-UV therapy is an underutilized therapeutic modality. According to a recent member survey by the National Psoriasis Foundation, many psoriasis patients are frustrated with available treatment options, which they perceive as ineffective, inconvenient, and/or excessively conservative. Treatment of psoriasis with acitretin in concert with UVB or PUVA is emerging as a viable clinical strategy. Compared with either acitretin or UV light monotherapy alone, the combination regimen enhances efficacy and limits treatment frequency, duration, and cumulative doses. These effects translate into care that is more effective, better tolerated, more convenient, less costly, and, perhaps, safer during long-term treatment than phototherapy alone. Drawing from an extensive literature search and the expertise of its participants, this consensus conference advances clinical recommendations as well as "clinical pearls" for health providers who treat patients with chronic, moderate to severe plaque psoriasis and suggests avenues for future research.
authors.affiliation: Department of Dermatology, Mount Sinai School of Medicine, New York University 10029-6574, USA.
authors.forename: M
authors.initials: M
authors.lastname: Lebwohl
authors.forename: L
authors.initials: L
authors.lastname: Drake
authors.forename: A
authors.initials: A
authors.lastname: Menter
authors.forename: J
authors.initials: J
authors.lastname: Koo
authors.forename: A B
authors.initials: AB
authors.lastname: Gottlieb
authors.forename: M
authors.initials: M
authors.lastname: Zanolli
authors.forename: M
authors.initials: M
authors.lastname: Young
authors.forename: P
authors.initials: P
authors.lastname: McClelland
mesh_terms: D017255:Acitretin / Q000008:administration & dosage / Q000627:therapeutic use*; D000287:Administration, Topical; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D007641:Keratolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D011379:Prognosis; D011565:Psoriasis / Q000628:therapy*; D014467:Ultraviolet Therapy
chemical_list: D007641:Keratolytic Agents; D017255:Acitretin